Cellgen

What Cellgen does

Cellgen (legal name: Centrum Patologii Molekularnej CELLGEN) is a privately held, specialized molecular pathology laboratory headquartered in Wrocław, Poland, founded and led by Dr Łukasz Fuławka. The company operates as an integrated diagnostic center combining histopathology, cytology, and molecular biology techniques, including Real-Time PCR, immunohistochemistry, and liquid-based cytology (LBC). Its clinical portfolio centers on cervical cancer screening (HPV genotyping for 14 high-risk types, LBC, CINtec PLUS immunocytochemistry), STI panels (Chlamydia, Mycoplasma, Neisseria gonorrhoeae, Trichomonas, Ureaplasma), histopathological consultations including professor-level reviews, and non-gynecological cytology. A distinctive operational asset is the on-site biobank — approximately 90,000 biological samples and over 2,000 digitized histopathological images — operated under BBMRI-ERIC standards since 2018.

Cellgen applies deep learning–based computer vision to microscopic image analysis, most notably a Ki-67 proliferation index assessment in breast cancer developed with Wrocław University of Science and Technology and published in Scientific Reports. The lab participates in international research collaborations, including the CRIT-CoV-U study with Medizinische Hochschule Hannover (published in The Lancet Digital Health), SARS-CoV-2 NGS analysis with the Institute of Bioorganic Chemistry PAN, and validation partnerships with Genomtec (RT-LAMP) and Vitassay (qPCR). It holds a Narodowy Fundusz Zdrowia (NFZ) contract for the Cervical Cancer Prevention Program and is QCMD 2021 SARS-CoV-2 EQA certified.

The company serves three customer segments: individual patients (direct access via phone, email, and the online results portal wyniki.cellgen.pl), physicians and outpatient clinics (individualized collaboration terms for diagnostic referrals and consultations), and academic/research institutions (collaborative R&D, biobanking access, AI image analysis). Its operating geography is concentrated in Lower Silesia, Poland. Pricing is quote-based and not publicly disclosed, with NFZ reimbursement covering a portion of cervical cancer screening services. The team is small (1–10 employees), and the company is privately held with no disclosed funding rounds, parent company, or institutional investors.

Name

Cellgen

Legal name

Centrum Patologii Molekularnej CELLGEN

Website

https://cellgen.pl

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Cellgen is a Wrocław-based molecular pathology laboratory offering histopathology, cytology, real-time PCR diagnostics, and biobanking services to patients, physicians, and research institutions, with NFZ-funded cervical cancer screening and AI-based image analysis.

Ownership category

akta.pro rank

Product category

Molecular Pathology Diagnostics

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

Keywords

• Molecular diagnostics
• Histopathology services
• Biobanking services
• Cervical cancer screening
• Digital pathology

Headquarters

HQ city

Wroclaw

HQ country

Poland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Diagnostic Laboratory Services: Specialized pathology and molecular diagnostics services including histopathology, cytology, HPV genotyping, STI testing. Services covered by NFZ (National Health Fund) contracts for cervical cancer prevention program, as well as private patient payments.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Cellgen is a specialized molecular pathology center offering integrated diagnostic services spanning histopathology, cytology, and molecular biology. Core services include HPV genotyping for 14 high-risk types, liquid-based cytology (LBC), Real-Time PCR-based STI testing panels, histopathological examinations, and biobanking. The center also conducts R&D and provides AI-based microscopic image analysis for research and clinical applications.

Product overview

Cellgen is a specialized Molecular Pathology Center offering integrated diagnostic services spanning molecular biology and histopathology. The core portfolio includes HPV genotyping (14 high-risk types), liquid-based cytology (LBC), CINtec PLUS immunocytochemistry, and STI testing panels—all supported by histopathological and immunohistochemical examination services. The center provides specialized consultations including professor-level histopathological reviews. An online results portal enables patient access to test outcomes. Cellgen operates a biobank with approximately 90,000 biological samples and 2,000+ digitized histopathological images, and applies AI/deep learning for microscopic image analysis in cancer diagnostics.

Differentiator

Problem solved

Functional benefit

Products and services

• HPV Genotyping 14 HR Types Molecular test detecting 14 high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) for cervical cancer risk assessment and prevention, intended for patients and referring physicians.
• Liquid-Based Cytology (LBC) More sensitive cervical cancer screening method than traditional cytology, recommended by the Polish Society of Pathologists, used for cervical cancer prevention in patients and through NFZ-covered screening.
• CINtec PLUS Roche Immunocytochemical test for detecting neoplastic changes caused by high-risk HPV at early stages, complementing liquid-based cytology for cervical screening patients.
• STI Basic Package Real-Time PCR-based detection of sexually transmitted infections including Chlamydia trachomatis, Mycoplasma genitalium, and Neisseria gonorrhoeae, for patients and referring physicians.
• Extended STI Panel Comprehensive sexually transmitted infection testing using Real-Time PCR detecting Chlamydia, Mycoplasma, Gonorrhea, Trichomonas, and Ureaplasma species, offered to patients and clinicians.
• Histopathological and Immunohistochemical Examination Specialized tissue pathology diagnostics using histological and immunohistochemical methods for disease diagnosis, serving referring physicians and clinics.
• Non-Gynecological Cytology Cytological examination services for non-gynecological samples including thyroid and other tissue types, provided for patients and referring physicians.
• Gynecological Cytology Cytological screening and diagnostic services for gynecological conditions, offered to patients and clinicians.
• Histopathological Consultation Specialist histopathological consultation services for difficult clinical cases, provided for referring physicians and patients.
• Professor Histopathological Consultation Senior academic specialist consultation for complex pathological cases, provided by Prof. Agnieszka Hałoń for referring physicians and patients.
• Biobank Services Biological material archiving services including approximately 90,000 banked samples and over 2,000 digitized histopathological images, following international BBMRI-ERIC standards; offered to research institutions, biotech and pharma partners.
• Online Results Portal Patient-accessible web portal for viewing laboratory test results online, supporting direct-to-patient diagnostic services.
• Cervical Cancer Prevention Program NFZ-funded prevention program covering HPV testing and liquid-based cytology (LBC) for cervical cancer screening, available to patients through the National Health Fund.

Quantifiable outcome

• Cervical cancer screening sensitivity improvement: LBC method detects abnormalities that traditional cytology (50-60% sensitivity) would miss
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Polska Sieć Biobanków / BBMRI-ERICcoreStrategic or Co-development Partner · 1 January 2018Member since 2018 of Polish Biobank Network based on European Research Infrastructure Consortium for Biobanking and Biomolecular Resources (BBMRI-ERIC). Ensures compliance with international standards for biological material collection and data security.
• VitassayminorStrategic or Co-development PartnerComparative study validating Vitassay qPCR kits for qualitative detection of SARS-CoV-2 virus from nasopharyngeal samples by comparing sensitivity and specificity against reference method (Real-Time RT-PCR).
• Genomtec S.A.coreStrategic or Co-development PartnerComparative study of Genomtec SARS-Cov-2 EvaGreen Direct-RT-LAMP CE-IVD Kit effectiveness for detecting SARS-CoV-2 directly in saliva samples versus standard Real-Time RT-PCR. Cellgen coordinates the study with Regionalne Centrum Naukowo-Technologiczne as second site.
• Medizinische Hochschule Hannover (MHH)coreStrategic or Co-development PartnerInternational CRIT-CoV-U study on validation of urine test for early and accurate prognosis of critical complications in patients with SARS-CoV-2 infection. First prospective clinical trial worldwide for predicting COVID-19 disease course using proteomic test CoV50.
• Wrocławskie Centrum AkademickieminorStrategic or Co-development PartnerCollaboration through MOZART program - scientific-business partnership support program funded by the City of Wrocław. Project on implementing additional quality control stage for genetic material in molecular tests to identify pre-laboratory errors.
• Politechnika Wrocławska (Wrocław University of Science and Technology)coreStrategic or Co-development PartnerCollaborative research project on 'Assessment of Ki-67 proliferation index in breast cancer using computer image analysis methods' resulting in publication in Scientific Reports (Nature group). Project led by Dr Łukasz Fuławka.
• Regionalne Centrum Naukowo-Technologiczne (RCNT)coreStrategic or Co-development PartnerCooperation agreement for mutual support in R&D projects. RCNT included as second site in Genomtec comparative study. Research cooperation in biobanking and scientific research.
• Instytut Chemii Bioorganicznej PAN (Institute of Bioorganic Chemistry, Polish Academy of Sciences)coreStrategic or Co-development PartnerScientific cooperation agreement for project 'Analysis of genetic variability and spread of SARS-CoV-2 virus in Poland using next-generation sequencing'. Goal: examining genetic profile differences of virus from different regions of Poland.
• Koalicja AI w zdrowiu (AI in Health Coalition)minorStrategic or Co-development PartnerMember of AI in Health Coalition recognizing Cellgen as specialized center combining molecular biology, pathomorphology, and computer-based microscopic image analysis. Biobank resources (biological material, clinical data, digitized histopathological images) seen as valuable source for AI-driven medical research development.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Others

• Hologic Inc. Global women's health diagnostics company whose ThinPrep liquid-based cytology (LBC) platform underpins one of Cellgen's core cervical screening offerings. A reagent/equipment supplier to Cellgen rather than a service competitor.
• Roche Diagnostics: Global in vitro diagnostics division supplying the CINtec PLUS immunocytochemistry test that Cellgen uses in cervical cancer screening. Functions as a technology/reagent supplier to Cellgen rather than a service competitor in Poland.
• Vitassay S.L. Spanish manufacturer of qPCR diagnostic kits, including the SARS-CoV-2 kits Cellgen helped validate. An R&D/validation partner and reagent supplier rather than a competing diagnostic service provider.

Broad incumbents

• QIAGEN N.V. Global molecular diagnostics company providing sample-prep and PCR/NGS reagents used in HPV, STI, and SARS-CoV-2 testing — categories Cellgen offers. Larger but adjacent positioning in the molecular diagnostics value chain that Cellgen participates in as a service provider.
• Diagnostyka S.A. Largest Polish network of medical diagnostic laboratories offering a broad test menu (pathology, molecular, imaging-support) across the country. Directly overlaps with Cellgen on histopathology, cytology, and molecular testing, but at national scale and far larger headcount.
• Foundation Medicine (Roche): Molecular profiling/diagnostics company (Roche subsidiary) operating central lab services for oncology. Comparable as a specialty molecular diagnostics lab, but at much larger scale and focused on oncology genomics rather than gynecological pathology.
• ALAB Laboratoria Sp. z o.o. Major Polish clinical laboratory chain with nationwide collection points and comprehensive diagnostic services including molecular diagnostics and pathology. Comparable as a Polish clinical lab competitor to Cellgen, but operates at significantly greater scale and breadth.
• Synevo (Medicover): Central and Eastern European clinical diagnostics network under Medicover, providing pathology, molecular and routine testing across multiple countries. Comparable business model (medical laboratory services) with much broader geographic footprint and portfolio than Cellgen.
• Labcorp Holdings: Global clinical laboratory network offering pathology, molecular diagnostics, and esoteric testing across North America and beyond. Comparable business model to Cellgen's clinical diagnostic services, but at vastly greater scale and global reach.

Direct peers

• Genomtec S.A. Wrocław-based molecular diagnostics company developing RT-LAMP point-of-care tests. Cellgen is a direct R&D partner for SARS-CoV-2 validation studies; both operate in molecular diagnostics with overlapping technologies (PCR vs. RT-LAMP) and target Polish/European clinical customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/cellgen.wroclaw
• LinkedInlinkedin.com/company/cellgen-laboratory

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellgen